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Background: Asthma is the most common chronic disease of childhood and a leading cause of childhood
morbidity. The aim of the current study was to assess the effectiveness of montelukast administered as
monotherapy or in combination with current inhaled corticosteroids (ICS) in pediatric patients with uncontrolled
asthma as per the Canadian Asthma Consensus Guidelines.
Methods: Twelve-week, multicentre, open-label, observational study. Primary effectiveness outcome was the
proportion of patients achieving asthma control (Asthma Control Questionnaire (ACQ) score ≤0.75) at weeks 4
and 12.
Results: A total of 328 patients with uncontrolled asthma (ACQ > 0.75) were enrolled with mean ± SD age of
6.9 ± 3.4 years. Among these, 76 (23.2%) were treated with montelukast monotherapy and 252 (76.8%) with
montelukast combined with ICS. By 4 weeks of treatment 61.3% and 52.9% of the patients in the monotherapy
and combination group, respectively, achieved asthma control. These proportions increased to 75.0% and 70.9%,
respectively, at 12 weeks. Within the monotherapy group, clinically significant improvements in the ACQ score
(mean ± SD of 1.67 ± 0.69, 0.71 ± 0.70 and 0.50 ± 0.52 at baseline, 4 and 12 weeks, respectively; p < 0.001) and the
PACQLQ score (mean ± SD of 5.34 ± 1.14, 6.32 ± 0.89 and 6.51 ± 0.85 at baseline, 4 and 12 weeks, respectively; p < 0.001)
were observed. In the combination group, the mean ± SD ACQ score significantly improved from 2.02 ± 0.83 at
baseline to 0.90 ± 0.86 at 4 weeks and 0.64 ± 0.86 at 12 weeks (p < 0.001), while the PACQLQ score improved
from 4.42 ± 1.35 at baseline to 5.76 ± 1.30 at 4 weeks and 6.21 ± 1.03 at 12 weeks (p < 0.001). After a 12-week
montelukast add-on therapy, 22.6% of patients reduced their ICS dosage. Similar results were observed among
preschool- and school-aged patients.
Conclusions: Montelukast as monotherapy or in combination with ICS represents an effective treatment
strategy for achieving asthma control in pediatric patients and improving caregivers’ quality of life.
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Asthma is a chronic inflammatory disorder of the airways
with a heterogeneous target age group and an initial diag-
nosis age of as early as infancy. Its prevalence, especially
among children, is increasing worldwide [1,2], including
Canada [3,4]. From 2000 to 2001, 13.4% of Canadian chil-
dren aged up to 11 years old were diagnosed with asthma
[3]. Relative to the 1994 to 1995 period, this represents a
statistically significant increase in the asthma prevalence
of nearly 70,000 diagnoses of asthmatic children [3],
rendering asthma one of the most prevalent chronic
conditions affecting Canadian children.
Current asthma treatment guidelines recognize the
importance of early and aggressive intervention for asthma
and recommend low-dose inhaled corticosteroids (ICSs) as
first-line treatment in childhood [2,5-8]. However, despite
ICS treatment, an important proportion of patients remain
with uncontrolled asthmatic symptoms. In addition, the
response to asthma therapy appears to be variable since
some asthmatic children who do not respond to ICSs may
respond to other therapies [9,10]. This further highlights
the need to identify alternative treatment strategies that
will expand the array of therapeutic options available to
physicians who treat pediatric asthma [11].
Leukotriene receptor antagonists (LTRAs), such as mon-
telukast, provide an alternative treatment for asthma
patients who are not controlled or satisfied with ICS
therapy [2,5-7,12]. Montelukast is an orally administered,
once-daily LTRA that can be prescribed as monotherapy
or in combination with other asthma medications, includ-
ing ICSs, for the treatment of asthma.
Although results from controlled randomized clinical
trials have provided evidence of the montelukast efficacy
in the treatment of asthmatic children [13,14], continuous
evaluation of the effectiveness and safety of montelukast
in a less controlled real-life setting is essential to help
health care professionals bridge the gap between current
knowledge and routine practice in the management of
asthmatic children. There is currently little information
available on montelukast effectiveness in every day prac-
tice for children, which could complement the findings of
randomized clinical trials. Therefore, the principal aim of
this study was to assess the effectiveness of montelukast
administered either as monotherapy or in combination
with current ICS treatment in pediatric patients with un-
controlled asthma, in a clinical setting emulating real-life.
Methods
Study design
This was a 12-week, open-label, multicenter, prospective
study conducted in 58 Canadian clinics between June
2006 and October 2008. Patients were treated with mon-
telukast sodium for 12 weeks, either as a monotherapy
or in combination with their current ICS treatment.Clinical assessments were conducted at baseline, 4 and
12 weeks of treatment at the clinics of their treating
physicians. During the course of the study, tapering of
ICS dosage was performed at the discretion of the
treating physician and on an individual basis when
asthma control was achieved. An optional visit after
8 weeks of treatment was performed to determine if an
ICS dosage adjustment was necessary and to assess
asthma control of patients previously tapered. Parents
or legal guardians provided written informed consent
prior to the participation of their children in this study.
The study was approved by three independent Ethics
Review Boards (IRB Services, Aurora, Ontario; the College
of Physicians and Surgeons of Alberta, Edmonton; and the
Comité central de l’éthique de la recherche du Ministère
de la santé et des services sociaux du Québec, Montréal,
Québec), and was conducted in accordance with ICH
Good Clinical Practice Guidelines, the World Medical
Association Declaration of Helsinki and all applicable
local regulations.
Patients
Eligible patients were between 2 and 14 years of age and
had been diagnosed with asthma for at least 6 months.
In order to be included in the study, patients had to have
a peak expiratory Flow (PEF) ≥ 80% of the predicted value
(applicable only for patients older than 7 years old) and
they had to be either currently untreated, using a short-
acting β2–agonist (SABA) on an as-needed basis or using
an ICS at any dosage. In addition, one of the following
conditions had to be satisfied: i) the physician and/or
patient was dissatisfied with the current controller therapy;
ii) the patient was reluctant to take ICS therapy, or; iii)
the patient was insufficiently controlled with the current
therapy through the preceding 6 weeks. Finally, eligible
patients had to have uncontrolled asthma as per the 2003
Canadian Asthma Consensus Guidelines [6].
Patients were excluded if their asthma symptoms were
controlled and if they were treated with montelukast or
any of the following treatments at the time of entry into
the study: long-acting β2-agonist (LABA) alone or in a
combination product, oral prednisone, regular use of
theophylline and/or other asthma medications such as
sodium cromoglycate or nedocromil. Patients using an
antibiotic for respiratory tract infection at the time of
entry into the study or treated with an antibiotic for re-
spiratory tract infection (initiation of antibiotic treat-
ment was permitted during the study) within 30 days
were also excluded. A history of cystic fibrosis, immune
deficiency requiring specific therapy or any other dis-
ease that could influence the evolution of asthma was
also a reason for exclusion. Finally, patients with a history
of hypersensitivity to any component of montelukast were
excluded.
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the proportion of patients achieving asthma control based
on the ACQ criteria (ACQ ≤ 0.75), a re-analysis of the data
was conducted including only patients with ACQ> 0.75 at
baseline the results of which are reported here.
Treatment strategies
All patients were treated with montelukast sodium (SIN-
GULAIR®, Merck & Co. Inc., USA) taken once-daily at
bedtime as monotherapy or in addition to their current
ICS therapy. Patients aged between 6 and 14 years were
treated with 5 mg montelukast sodium chewable tablets,
while patients between 2 and less than 6 years of age
were treated with 4 mg montelukast chewable tablets.
The 4 mg granule formulation was also available for the
latter age group on demand. The use of a short-acting
β2-agonist (SABA) as rescue medication was allowed
during the study, but patients were asked to refrain from
its utilization for 6 hours prior each study visit.
Outcome measures
The primary effectiveness outcome measures was the
proportion of patients achieving asthma control, defined
as a score ≤ 0.75 [15] in the self-administered Asthma
Control Questionnaire (ACQ) (completed by the patient
or their caregiver) [16]. Secondary effectiveness outcome
measures included: (i) the mean change in ACQ score
between baseline and the 4- and 12-week assessments,
considering a change of ≥ 0.5 in ACQ score as clinically
important [16]; (ii) the change in quality of life of the
caregivers between baseline and the 4- and 12-week
assessments, as assessed using the Pediatric Asthma
Caregivers Quality of Life Questionnaire (PACQLQ)
[17], considering changes of ≥ 0.7 in PACQLQ as clinically
important [17]; (iii) the patient (completed by the patient
or their caregiver) and physician satisfaction with treat-
ment as measured using the 5-point Likert scale ranging
from 0 (very dissatisfied) to 4 (very satisfied), upon 4 and
12 weeks of treatment with montelukast; and (iv) the pro-
portion of patients on montelukast combination therapy
whose baseline ICS daily dosage was tapered to a lower
ICS dose category after 4, 8 and 12 weeks of treatment.
The ICS daily doses were categorized according to the
2006 report of the Global Initiative for Asthma (GINA)
[18] as follows: (i) low dose, defined as ≤200 μg/day of flu-
ticasone propionate or equivalent (≤200 μg/day of beclo-
methasone dipropionate and ≤200 μg/day of budesonide);
(ii) moderate dose, defined as >200 to ≤500 μg/day of
fluticasone propionate or equivalent (>200 to ≤400 μg/day
of beclomethasone dipropionate and >200 to ≤400 μg/day
of budesonide); and (iii) high dose, defined as >500 μg/day
of fluticasone propionate or equivalent (>400 μg/day
of beclomethasone dipropionate and >400 μg/day of
budesonide).Compliance with the study medication was assessed by
tablet counts, as recorded in the study worksheets.
Safety and tolerability were assessed with the incidence
of treatment-emergent adverse events, which were coded
and reported according to the MedDRA dictionary of
terms, version 9.0 [19].
Statistical methods
Descriptive statistics were produced for patient demo-
graphics and characteristics at baseline. Comparisons
between baseline and follow-up visits were performed
with the matched Chi-Square test for categorical scales
and the paired Student’s t-test for continuous scales.
Two-tailed tests were performed using a significance
level (α) of 0.05. Subgroup analyses by treatment strategy
and stratified analyses for preschool-aged children (less
than 6 years old) and school-aged children (6 years of age
or older) were performed. There were no imputations for
missing data. All analyses were performed using the SPSS
version 12.0 for Windows (SPSS Inc., Chicago, IL).
Results
Patient disposition
A total of 420 patients with uncontrolled asthma as per the
2003 Canadian Asthma Consensus Guidelines completed
the baseline assessment of whom 92 (21.9%) had an ACQ
score of ≤ 0.75 at baseline. Considering that the primary
outcome measure was the proportion of patients achieving
asthma control based on the ACQ criteria, only the 328
patients with ACQ> 0.75 were included in this analysis.
Among these, 320 (97.6%) and 288 (87.8%) patients com-
pleted the 4- and 12-week assessment, respectively, while
the optional 8-week assessment was performed on 197
(60.1%) patients. There were 40 (12.2%) patients who were
discontinued from the study: 10 (3.0%) due to an adverse
event, 8 (2.4%) withdrew consent, 9 (2.7%) were lost to
follow-up, 4 (1.2%) due to protocol violation, 8 (2.4%)
discontinued for other reasons, while the reason of dis-
continuation was missing for 1 (0.3%) patient.
Patient demographics and baseline characteristics
The demographics and baseline characteristics of the study
population are summarized in Table 1. The mean (SD) age
was 6.92 (3.35) years, 192 (58.5%) patients were male and
209 (63.7%) were Caucasian. At baseline, 252 patients were
on ICS therapy and were therefore included in the monte-
lukast add-on group, the majority of whom were taking
moderate doses of ICS (n = 143; 56.7%). The remaining
76 patients were not taking ICS at baseline and com-
prised the montelukast monotherapy treatment group.
Overall, at baseline, 269 (82.0%) patients had night-
time symptoms ≥ 1 night/week, 247 (75.3%) had daytime
symptoms ≥ 4 days/week, and 122 (37.2%) reported absen-
teeism from school in the last week due to asthma.
Table 1 Demographics and baseline characteristics
Characteristics Montelukast monotherapy Montelukast + ICS Total
Preschool age School age All Preschool age School age All
N 34 42 76 112 140 252 328
Age (years), mean (SD) 4.01 (1.12) 9.19 (2.26) 6.87 (3.19) 3.86 (1.13) 9.54 (2.35) 7.02 (3.41) 6.92 (3.35)
Gender, n (%)
Male 18 (52.9) 25 (59.5) 43 (56.6) 60 (53.6) 89 (63.6) 149 (59.1) 192 (58.5)
Female 16 (47.1) 17 (40.5) 33 (43.4) 52 (46.4) 51 (36.4) 103 (40.9) 136 (41.5)
Race, n (%)
Caucasian 25 (73.5) 32 (76.2) 57 (75.0) 66 (58.9) 86 (61.4) 152 (60.3) 209 (63.7)
Black 0 (0.0) 1 (2.4) 1 (1.3) 8 (7.1) 13 (9.3) 21 (8.3) 22 (6.7)
Asian 4 (11.8) 8 (19.0) 12 (15.8) 32 (28.6) 32 (22.9) 64 (25.4) 76 (23.2)
Hispanic 0 (0.0) 1 (2.4) 1 (1.3) 3 (2.7) 3 (2.1) 6 (2.4) 7 (2.1)
Other 3 (8.8) 0 (0.0) 3 (3.9) 2 (1.8) 6 (4.3) 8 (3.2) 11 (3.4)
Missing 2 (5.9) 0 (0.0) 2 (2.6) 1 (0.9) 0 (0.0) 1 (0.4) 3 (0.9)
Duration of asthma since diagnosis (years),
mean (SD)
2.06 (1.11) 4.32 (3.25) 3.31 (2.76) 2.11 (1.27) 5.46 (3.08) 3.97 (2.96) 3.82 (2.92)
Smoking history, n (%)
Patient is a smoker 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Patient quit smoking 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.4) 1 (0.3)
Patient never smoked 34 (100.0) 41 (97.6) 75 (98.7) 104 (92.9) 133 (95.0) 237 (94.0) 312 (95.1)
Member of household is a smoker 8 (23.5) 14 (33.3) 22 (28.9) 20 (17.9) 40 (28.6) 60 (23.8) 82 (25.0)
Member of household quit smoking 5 (14.7) 11 (26.2) 16 (21.1) 8 (7.1) 7 (5.0) 15 (6.0) 31 (9.5)
Use of ICS at baseline, n (%)
Low dose* - - - 58 (51.8) 39 (27.9) 97 (38.5) 97 (29.6)
Moderate dose† - - - 53 (47.3) 90 (64.3) 143 (56.7) 143 (43.6)
High dose‡ - - - 1 (0.9) 11 (7.9) 12 (4.8) 12 (3.7)
Profile of asthma symptoms, n (%)
1. Daytime symptoms ≥ 4 days/week 24 (70.6) 26 (61.9) 50 (65.8) 91 (81.3) 106 (75.7) 197 (78.2) 247 (75.3)
2. Night-time symptoms≥ 1 night/week 29 (85.3) 30 (71.4) 59 (77.6) 99 (88.4) 111 (79.3) 210 (83.3) 269 (82.0)
3. Absenteeism from school due to asthma in the
last week
7 (20.6) 16 (38.1) 23 (30.3) 33 (29.5) 66 (47.1) 99 (39.3) 122 (37.2)
4. SABA ≥ 4 doses in the last week§ 13 (38.2) 13 (31.0) 26 (34.2) 76 (67.9) 92 (65.7) 168 (66.7) 194 (59.1)
5. FEV in one second or PEF ≥90% of their personal
best in the last week
2 (5.9) 9 (21.4) 11 (14.5) 11 (9.8) 41 (29.3) 52 (20.6) 63 (19.2)
6. Diurnal variability in peak expiratory flow >10%
to 15% in the last week
2 (5.9) 2 (4.8) 4 (5.3) 8 (7.1) 22 (15.7) 30 (11.9) 34 (10.4)
*Low dose was defined as ≤ 200 μg/day for fluticasone propionate or equivalent (≤200 μg/day for beclomethasone dipropionate and ≤200 μg/day for budesonide).
†Moderate dose was defined as >200 to 500 μg/day for fluticasone propionate or equivalent (>200 to 400 μg/day for beclomethasone dipropionate and >200 to
400 μg/day for budesonide) [18].
‡High dose was defined as > 500 μg/day for fluticasone propionate or equivalent (>400 μg/day for beclomethasone dipropionate and >400 μg/day
for budesonide).
§Excluding one dose/day before exercise.
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was reported twice as frequently by patients in the
combination therapy compared to the monotherapy
group (66.7% vs 34.2%).
Effectiveness outcomes
Table 2 presents the proportions of patients who achieved
asthma control after 4 and 12 weeks of treatment with
montelukast, administered either as a monotherapy or inaddition to ICS therapy, overall and stratified by treatment
strategy and age group. The overall proportion of patients
who achieved asthma control (ACQ score ≤ 0.75) was
54.9% (n = 175) at 4 weeks and 71.9% (n = 207) at 12 weeks.
Among preschool patients, the proportion of patients with
controlled asthma increased from 63.3% (n = 88) at 4 weeks
to 77.3% (n = 99) at 12 weeks, while among school aged
patients, these proportions were 48.3% (n = 87) and 67.5%
(n = 108), respectively. This significant rate of asthma
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montelukast alone and in combination with ICS.
The mean (SD) ACQ score of the total study sample
decreased from 1.94 (0.82) at baseline to 0.85 (0.83) at
4 weeks and 0.61 (0.79) at 12 weeks of treatment, repre-
senting statistically and clinically significant absolute mean
(SD) changes of −1.08 (1.00) and −1.34 (1.03) from base-
line to 4 and 12 weeks, respectively (p < 0.001) (Table 3).
Among the patients treated with montelukast monother-
apy, the mean (SD) ACQ score significantly decreased
from 1.67 (0.69) at baseline to 0.71 (0.70) at 4 weeks and
to 0.50 (0.52) 12 weeks (Figure 1A). Among the patients
treated with the montelukast add-on treatment strategy,Table 2 Proportion of patients with asthma control
(ACQ score ≤ 0.75)
Asthma control
4 weeks 12 weeks
n % n %
Montelukast monotherapy
All patients, n (%) (N = 75) (N = 68)
Well controlled 46 61.3 51 75.0
Not controlled 29 38.7 17 25.0
Preschool aged patients, n (%) (N = 34) (N =32 )
Well controlled 19 55.9 24 75.0
Not controlled 15 44.1 8 25.0
School aged patients, n (%) (N =41 ) (N = 36)
Well controlled 27 65.9 27 75.0
Not controlled 14 34.1 9 25.0
Montelukast + ICS
All patients, n (%) (N = 244) (N = 220)
Well controlled 129 52.9 156 70.9
Not controlled 115 47.1 64 29.1
Preschool aged patients, n (%) (N = 105) (N = 96)
Well controlled 69 65.7 75 78.1
Not controlled 36 34.3 21 21.9
School aged patients, n (%) (N = 139) (N = 124)
Well controlled 60 43.2 81 65.3
Not controlled 79 56.8 43 34.7
Total study sample (Montelukast monotherapy & Montelukast + ICS)
All patients, n (%) (N = 319) (N = 288)
Well controlled 175 54.9 207 71.9
Not controlled 144 45.1 81 28.1
Preschool aged patients, n (%) (N = 139) (N = 128)
Well controlled 88 63.3 99 77.3
Not controlled 51 36.7 29 22.7
School aged patients, n (%) (N = 180) (N = 160)
Well controlled 87 48.3 108 67.5
Not controlled 93 51.7 52 32.5the mean (SD) ACQ score significantly decreased from
2.02 (0.83) at baseline to 0.90 (0.86) at 4 weeks and to 0.64
(0.86) at 12 weeks (Figure 1B).
The mean ACQ scores throughout the treatment period
for the monotherapy and combination therapy patients,
stratified by age group are also shown in Figure 1A and B.
Among preschool and school-aged patients treated with
montelukast monotherapy, the mean (SD) ACQ score sig-
nificantly decreased from 1.68 (0.75) and 1.66 (0.65) at
baseline to 0.79 (0.76) and 0.64 (0.65) at 4 weeks, to 0.54
(0.59) and 0.47 (0.45) at 12 weeks (Figure 1A), represent-
ing statistically and clinically significant absolute mean
(SD) changes of −1.13 (0.94) and −1.18 (0.64) from base-
line to 12 weeks, respectively (Table 3). Similarly, statisti-
cally and clinically significant decreases in the ACQ score
were also observed among preschool and school aged pa-
tients treated with montelukast add-on therapy (Figure 1B
and Table 3). Among children 7 years of age or older the
PEF assessment showed a statistically significant improve-
ment increasing from 253.9 L/min at baseline to 275.0 L/
min at 12 weeks of treatment (P < 0.001).
The mean (SD) PACQLQ score of the total study sam-
ple increased from 4.63 (1.36) at baseline to 5.89 (1.24)
at 4 weeks (mean (SD) change = 1.55 (1.40); P < 0.001)
and 6.28 (1.00) at 12 weeks (mean (SD) change = 1.82
(1.30); P < 0.001). Among the patients who adopted the
montelukast monotherapy treatment strategy, the mean
(SD) PACQLQ score increased from 5.34 (1.14) at baseline
to 6.32 (0.89) at 4 weeks and 6.51 (0.85) at 12 weeks. The
absolute mean (SD) change in PACQLQ of 0.98 (1.12) at
4 weeks and 1.13 (1.04) at 12 weeks was both clinically
(change in PACQLQ > 0.7) and statistically significant
(p < 0.001) (Table 3). Among the patients who adopted
the montelukast add-on treatment strategy, the mean
(SD) PACQLQ score increased from 4.42 (1.35) at base-
line to 5.76 (1.30) at 4 weeks and 6.21 (1.03) at 12 weeks
corresponding to a mean (SD) absolute change of 1.34
(1.34) at 4 weeks and 1.78 (1.36) at 12 weeks (p < 0.001)
(Table 3). In both treatment strategies, significant changes
were observed in both the emotional and activity limita-
tion domains of the PACQLQ questionnaire. Comparable
clinically and statistically significant changes in PACQLQ
scores were observed among preschool and school aged
patients (Figure 2A and B and Table 3).
Figures 3 and 4 summarize the results of the patients
and physicians global satisfaction with montelukast, re-
spectively. At baseline, 54.9% of the patients were dissatis-
fied or very dissatisfied with their current asthma therapy
and 12.8% were satisfied or very satisfied. After 4 and
12 weeks of treatment with montelukast, 8.8% and 2.4% of
the patients were dissatisfied/very dissatisfied and 73.9%
and 85.3% were satisfied/very satisfied, respectively. With
regards to the physician’s global satisfaction, 74.6% of the
treating physicians were dissatisfied or very dissatisfied
Table 3 Mean change in Asthma Control Questionnaire and Pediatric Asthma Caregivers Quality of Life Questionnaire
Age group Treatment group Total
Montelukast monotherapy Montelukast + ICS
Mean SD Mean SD Mean SD
All patients
ACQ score*
Change between Week 4 and Baseline −0.95 0.88 −1.12 1.03 −1.08 1.00
Change between Week 12 and Baseline −1.15 0.79 −1.40 1.09 −1.34 1.03
PACQLQ score*
Change between Week 4 and Baseline 0.98 1.12 1.34 1.34 1.25 1.30
Change between Week 12 and Baseline 1.13 1.04 1.78 1.36 1.63 1.32
Emotional function*
Change between Week 4 and Baseline 0.90 1.14 1.25 1.32 1.17 1.29
Change between Week 12 and Baseline 1.02 1.01 1.71 1.41 1.55 1.36
Activity limitation*
Change between Week 4 and Baseline 1.16 1.32 1.53 1.61 1.44 1.55
Change between Week 12 and Baseline 1.38 1.34 1.94 1.51 1.81 1.49
Pre-School patients
ACQ score*
Change between Week 4 and Baseline −0.89 1.10 −1.38 1.08 −1.26 1.11
Change between Week 12 and Baseline −1.13 0.94 −1.56 1.16 −1.45 1.12
PACQLQ score*
Change between Week 4 and Baseline 1.01 1.19 1.73 1.42 1.55 1.40
Change between Week 12 and Baseline 1.18 1.06 2.03 1.30 1.82 1.30
Emotional function*
Change between Week 4 and Baseline 0.88 1.16 1.60 1.41 1.42 1.39
Change between Week 12 and Baseline 1.05 0.95 1.94 1.34 1.72 1.31
Activity limitation*
Change between Week 4 and Baseline 1.29 1.40 2.02 1.62 1.84 1.60
Change between Week 12 and Baseline 1.47 1.47 2.24 1.45 2.05 1.49
School aged patients
ACQ score*
Change between Week 4 and Baseline −1.01 0.64 −0.93 0.94 −0.94 0.88
Change between Week 12 and Baseline −1.18 0.64 −1.27 1.02 −1.25 0.95
PACQLQ score*
Change between Week 4 and Baseline 0.96 1.08 1.04 1.20 1.02 1.17
Change between Week 12 and Baseline 1.09 1.03 1.58 1.37 1.47 1.31
Emotional function*
Change between Week 4 and Baseline 0.92 1.14 0.99 1.19 0.97 1.18
Change between Week 12 and Baseline 1.00 1.08 1.53 1.44 1.41 1.38
Activity limitation*
Change between Week 4 and Baseline 1.04 1.26 1.15 1.49 1.13 1.44
Change between Week 12 and Baseline 1.29 1.23 1.70 1.52 1.61 1.47
*P < 0.001 for all changes from baseline based on Student’s t-test for Paired Observations.
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satisfied or very satisfied at baseline. After 4 and 12 weeks
of treatment with montelukast, 8.3% and 4.1% of the phy-
sicians were dissatisfied/very dissatisfied while 66.6% and
87.8% were satisfied/very satisfied, respectively. Overall,
the changes in patient and physician satisfaction upon
treatment with montelukast for 4 and 12 weeks were
statistically significant (p < 0.001) without any significant
differences between preschool and school aged patients
(data not shown).
The proportions of patients who tapered their baseline
ICS daily dosage use to a lower ICS dose category after
adding montelukast to their treatment regimen are re-
ported in Table 4. There were 45 (18.4%), 40 (25.2) and 44
(20.0) patients who reduced their ICS dosage after the
addition of montelukast to their current ICS treatmentregimen at 4, 8 and 12 weeks, respectively. Similar results
were observed for preschool and school aged patients.
Treatment compliance and safety
Compliance with the treating regimen was high during
the follow-up period with patients taking by average
91.6%, 93.6% and 92.2% of their prescribed doses upon
4, 8 and 12 weeks of treatment, respectively. During the
course of the study, there were 182 non-serious adverse
events (NSAEs) reported by 112 (34.1%) patients. Of
these, 157 (86.3%) were probably or definitely not
related to study medication and 15 led to study drug dis-
continuation in 12 (3.7%) patients. There were 25
(13.7%) NSAEs possibly, probably or definitely related to
montelukast. Of these, the most frequent NSAEs related
to montelukast were nightmares and sleep terror (n = 6),
A B
Figure 1 Mean Asthma Control Questionnaire (ACQ) score over time. A) Montelukast monotherapy; B) Montelukast + ICS.
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http://www.aacijournal.com/content/10/1/21abdominal pain (n = 5), insomnia (n = 2) and headache
(n = 2). A total of 3 serious adverse events (SAEs) were
experienced by 3 patients: 1 asthma episode, 1 bronchitis
and 1 pneumonia, none of which were judged to be
related to the study medication by the treating
physicians.A
Figure 2 Mean Pediatric Asthma Caregivers Quality of Life Questionn
B) Montelukast + ICS.Discussions
Although results from controlled randomized clinical
trials indicate that montelukast is efficacious in the
treatment of asthmatic children [13,14], continuous evalu-
ation of the effectiveness and safety of montelukast in a
less controlled real-life setting is essential in order to helpB


















Week-0 (without montelukast) Week-4 (with montelukast) Week-12 (with montelukast)
Figure 3 Patient global satisfaction upon treatment with montelukast. Note: Percentages were calculated on available observations.
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http://www.aacijournal.com/content/10/1/21health care professionals bridge the gap between current
knowledge and practice in the management of asthmatic
children. Accordingly, the principal objective of this study
was to assess the effectiveness of montelukast adminis-
tered either as a monotherapy or in combination with ICS
treatment in children with uncontrolled asthma. Further-
more, in line with the fact that recommendations for
asthma treatment differ according to children age categor-
ies [5,8,20], the effectiveness assessments of montelukast
asthma treatment strategies were stratified by preschool


















Week-0 (without montelukast) Week-4 (
Figure 4 Physician global satisfaction with utilization of montelukast.The results of this 12-week multicenter observational
study support the therapeutic effectiveness of montelu-
kast in pediatric patients with uncontrolled asthma, in a
clinical setting emulating real-life. Asthma control was
achieved by the majority of patients who received mon-
telukast either as monotherapy or in combination with
ICS treatment for 12 weeks. Furthermore, clinically and
statistically significant decreases in ACQ scores were
observed after 4 and 12 weeks of treatment with monte-
lukast mono- and add-on therapies, among both preschool
and school-aged patients. satisfied or
satisfied
Satisfied Very satisfied
with montelukast) Week-12 (with montelukast)
Note: Percentages were calculated on available observations.
Table 4 Proportion of patients who tapered their dosage
of inhaled corticosteroids in the montelukast add-on
group
Duration of treatment
Baseline 4 weeks 8 weeks 12 weeks
All patients 328 320 197 288
Use of ICS, n
Yes 252 245 159 220
No 76 75 38 68
Tapered ICS, n (%)
Yes* - 45 (18.4) 40 (25.2) 44 (20.0)
No - 194 (79.2) 117 (73.6) 175 (79.5)
Missing - 6 (2.4) 2 (1.3) 1 (0.5)
Preschool aged patients 146 140 93 128
Use of ICS, n
Yes 112 106 72 96
No 34 34 21 32
Tapered ICS, n (%)
Yes† - 21 (19.8) 20 (27.8) 19 (19.8)
No - 82 (77.4) 50 (69.4) 76 (79.2)
Missing - 3 (2.8) 2 (2.8) 1 (1.0)
School aged patients 182 180 104 160
Use of ICS, n
Yes 140 139 87 124
No 42 41 17 36
Tapered ICS, n (%)
Yes‡ - 24 (17.3) 20 (23.0) 25 (20.2)
No - 112 (80.6) 67 (77.0) 99 (79.8)
Missing - 3 (2.2) 0 (0.0) 0 (0.0)
*There were 45 patients who newly tapered their ICS at 4 weeks, 17 at
8 weeks and 9 at 12 weeks.
†There were 21 preschool aged patients who newly tapered their ICS at
4 weeks, 8 at 8 weeks and 3 at 12 weeks.
‡There were 24 school aged patients who newly tapered their ICS at 4 weeks,
9 at 8 weeks and 6 at 12 weeks.
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differences in study designs and diversity in efficacy out-
comes, the results of the current study are consistent with
the efficacy profiles of montelukast in childhood asthma
that were previously reported in systematic reviews
and randomized clinical trials conducted in preschool
[11,13,21,22] and school-aged [11,14,22-28] children.
Furthermore, the observed ACQ improvement is signifi-
cantly higher to that observed with placebo in clinical tri-
als with comparable follow-up schedules to the current
study [29,30]. In addition, our findings provide further
evidence of the benefits of montelukast administered
either as monotherapy or in combination with ICS in
everyday childhood asthma management and real-life
clinical practices.Asthma is the most common chronic disease of
childhood and a leading cause of childhood morbidity.
In addition to considerably affecting children’s physical,
emotional and social lives, uncontrolled asthma also
directly correlates with a loss of productivity and quality
of life of the children’s caregivers [31,32]. Therefore, an ef-
fective strategy for the management of pediatric asthma
should involve the development of an effective, conveni-
ent, safe and well tolerated pharmacologic intervention
while improving the quality of life of the children and
their caregivers.
The results of this study indicate that both asthmatic
children and their caregivers can benefit from montelu-
kast therapy since it is an effective treating option enabling
asthma control, while significantly improving the care-
givers’ quality of life. After 12 weeks of treatment with
montelukast administered as monotherapy or in com-
bination with ICS, clinically (mean change of ≥ 0.7 in
PACQLQ score) and statistically (p < 0.001) significant
improvements in caregivers’ quality of life were observed
with mean (SD) changes in PACQLQ score of 1.25 (1.30)
and 1.63 (1.32) from baseline, respectively.
Furthermore, the vast majority of the patients and
physicians were satisfied or very satisfied with monte-
lukast. This high level of satisfaction can be probably
attributed to the observed effectiveness of montelukast
in controlling asthma symptoms and improving caregivers’
quality of life, the ease of medication administration which
enhances treatment compliance, and the safety and toler-
ability profile of montelukast.
The results of previous randomized clinical trials
conducted with adult asthmatic patients suggested that
montelukast could facilitate a reduction in ICS use
[33,34]. However, the evidence on the ICS-sparing effect
of montelukast in children is sparse and inconsistent.
While Strunk RC et al. [35] reported that montelukast
is not an effective ICS-sparing alternative in children,
Tamesis GP et al. [36] have shown significantly lower
use of supplemental ICS by children when montelukast
was added to their ICS treatment. Moreover, although
Phipatanakul W et al. [27] reported a non-significant
reduction of ICS dose, they observed that children
aged between 6 and 14 years experienced by average a
17% decrease in their ICS dose. In the current study
the potential ICS-sparing effect of montelukast in children
with uncontrolled asthma was also examined. In order to
better reflect the everyday clinical practice, ICS tapering
guidelines were distributed to treating physicians and the
decision of tapering the ICS dosage was left to the discre-
tion of the physician and made on an individual basis.
After 12 weeks of treatment with montelukast in combin-
ation with ICS, 71 (21.6%) children reduced their ICS daily
dosage. These results further reinforce the potential ICS-
sparing benefit of montelukast in asthma childhood.
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12 weeks was well tolerated in the context of this study.
The observed safety and tolerability results are consistent
with the safety profile of montelukast previously reported
in asthma childhood [2,13,14,22,24-26,37-39].
Potential limitations of the current study are related to
the open-label and single cohort design without a parallel
control group. However, since this study emulated the
real-world clinical setting, blinding to the treatment used
and comparison to a control group were not appropriate.
Furthermore, the primary objective of the study was to
assess the real-life effectiveness of treatment with monte-
lukast in achieving asthma control and not the compari-
son of montelukast treatment with alternate treatment
strategies. By conducting within- instead of between-group
comparison, possible confounding bias related to disease
and lifestyle factors that could affect the effectiveness of
montelukast were minimized since each patient provided
both control (pre-treatment) and on-treatment data. In
light of the heterogeneous response documented for both
ICS [39,40] and leukotriene receptor antagonist [39] treat-
ments, and the real-life practice in which physicians often
switch treatment in patients who are not responding or
adhering to their current therapy, there may be concerns
that the selected patients may have been more likely to
respond to montelukast treatment. However, treatment
response could not have been foreseen as no patient char-
acteristics are currently known to predict response to
montelukast [41]. The follow-up schedule recommended in
the current study may not be representative of Canadian
routine clinical practice which may have resulted in in-
creased adherence with treatment and, thus, treatment
effectiveness compared to that observed in real-life.
Observational studies are required in order to substan-
tiate this hypothesis. However, frequent assessment of
uncontrolled asthma should be encouraged given that
uncontrolled asthma has been shown to predict future
risk of instability and exacerbations [42]. Finally, in the
current analysis 92 (21.9%) patients who had an ACQ
score of ≤ 0.75 at baseline were excluded. This was due
to the fact that, although the primary outcome measure
was the proportion of patients achieving asthma control
based on the ACQ criteria, in order to be eligible for the
study patients had to have uncontrolled asthma as per
the Canadian Asthma Consensus Guidelines. However,
it should be noted that both analyses gave comparable
results.
An important strength of this study is the generalizability
of its results to the Canadian target population. Since this
study was conducted in a real-life clinical setting, inclusion
and exclusion criteria were less selective and therefore
more representative of the general population compared
to the highly controlled environment of clinical trials. In
addition, as recommended by the Global Initiative forAsthma (GINA), the current study focused on asthma
control achievement rather than on asthma severity
[2,5,8]. The effectiveness of montelukast in controlling
asthma symptoms was assessed with the asthma control
questionnaire (ACQ), a cost-effective [43] and validated
questionnaire [15,16,43]. Since there are no reliable or
validated measures of pulmonary airways function in
preschool children younger than 6 years old [44] and
given that the omission of the question on the forced
expiratory volume from the seven-item ACQ does not
alter the validity and the measurement properties of the
instrument [45], the use of ACQ for assessing asthma
effectiveness outcomes is considered suitable for the
real-life clinical management of childhood asthma. Finally,
the use of standardized and validated questionnaires to
assess asthma control (ACQ) [15,16,43] and caregiver’s
quality of life (PACQLQ) [17], also enhances the internal
validity of the study.
Conclusions
In conclusion, the results of this study indicate that mon-
telukast, administered either as monotherapy or in com-
bination with ICS treatment, is an effective, convenient
and well tolerated therapeutic option for the management
of asthma in preschool and school aged paediatric patients
with uncontrolled asthma symptoms.
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